Evidence map›Paper›PMID 39011838›Full record

ArticleClinical cardiology2024

Right Ventricular-Pulmonary Arterial Coupling and Outcome in Heart Failure With Preserved Ejection Fraction.

Jia Wang, Xiang Li, Jiahui Jiang, Ze Luo, Xilun Tan, Ruhua Ren, Tsutomu Fujita, Yoshifumi Kashima, Tetsuaki Li Tanimura, Ming Wang and 1 more

Abstract read
In one paragraph

Article in Clinical cardiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Ghrelin peptide in heart failure: when is showtime?Frontiers in cardiovascular medicine · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jia WangEmergency Department, Wangjing Hospital of China Academy of Chinese Medical Sciences, Beijing, China.ORCID http://orcid.org/0009-0000-6029-2242
Xiang LiDepartment of Cardiology, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, China.
Jiahui JiangDepartment of Cardiology, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, China.
Ze Luo
Xilun TanCollege of Traditional Chinese Medicine, Chongqing Medical University, Chongqing, China.
Ruhua RenEmergency Department, Wangjing Hospital of China Academy of Chinese Medical Sciences, Beijing, China.
Tsutomu FujitaDepartment of Cardiology, Sapporo Cardio Vascular Clinic, Sapporo, Japan.
Yoshifumi KashimaDepartment of Cardiology, Sapporo Cardio Vascular Clinic, Sapporo, Japan.
Tetsuaki Li TanimuraDepartment of Cardiology, Sapporo Cardio Vascular Clinic, Sapporo, Japan.
Ming WangDepartment of Cardiology, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, China.
Chenhao ZhangEmergency Department, Wangjing Hospital of China Academy of Chinese Medical Sciences, Beijing, China.

Funding

This study was sponsored by Capital's Funds for Health Improvement and Research (No. 2022-1-4161) and the Natural Science Foundation of Chongqing, China (cstc2019jcyj-msxmX0662).
6 · The paper itself

Abstract

backgroundRight ventricular-pulmonary artery coupling (RVPAC) refers to the relationship between right ventricular systolic force and afterload. The ratio of echocardiograph-derived tricuspid annular plane systolic excursion (TAPSE) to pulmonary artery systolic pressure (PASP) has been proposed as a noninvasive measurement of RVPAC and reported as an independent prognostic parameter of heart failure. However, it has not been adequately in detail evaluated in heart failure with preserved ejection fraction (HFpEF). We hypothesized that RVPAC may be used and proposed as an expression of key risk factors in patients with HFpEF.

methodsWe retrospectively analyzed TAPSE/PASP of 648 HFpEF patients hospitalized in Chongqing Hospital of Traditional Chinese Medicine from January 1, 2016 to January 1, 2017. All eligible patients were followed up for 5 years. The correlation between TAPSE/SPAP index and clinical indicators and outcomes was evaluated.

resultsThe final analysis included 414 patients. Nonsurvivors had significantly lower TAPSE, TAPSE/PASP and higher PASP compared with survivors (p < 0.0001). ROC curve analysis showed that the optimal cutoff of TAPSE, PASP, and RVPAC to predict all-cause death were 16.5 mm, 37.5 mmHg, and 0.45 mm/mmHg, respectively. In multivariate Cox regression analyses adjusted for gender showed a significant, independent association of the RVPAC with the composite endpoint of all-cause death or HF-related recurrent hospitalization (HR: 0.006; 95% CI 0.001-0.057, p < 0.001).

conclusionsRVPAC, defined by the ratio of TAPSE to PASP, is the expression of a key risk factor in HFpEF patients, which is independently associated with the composite endpoint of all-cause death or HF-related recurrent hospitalization.

Indexed as

Heart FailurePulmonary ArteryStroke VolumeVentricular Function, RightAgedChinaEchocardiographyFemaleFollow-Up StudiesHeart VentriclesHumansMaleMiddle AgedPrognosisRetrospective StudiesRisk Factorsechocardiographyheart failurepreserved ejection fractionright ventricular–pulmonary arterial coupling

Identifiers

PMID39011838
PMCPMC11249816

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.